{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T13:28:28Z","timestamp":1773149308402,"version":"3.50.1"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,6]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Neonatal candidiasis causes significant morbidity and mortality in high risk infants. The micafungin dosage regimen of 10\u2009mg\/kg established for the treatment of neonatal candidiasis is based on a laboratory animal model of neonatal hematogenous <jats:italic toggle=\"yes\">Candida<\/jats:italic> meningoencephalitis and pharmacokinetic (PK)\u2013pharmacodynamic (PD) bridging studies. However, little is known about the how these PK\u2013PD data translate clinically.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Micafungin plasma concentrations from infants were used to construct a population PK model using Pmetrics software. Bayesian posterior estimates for infants with invasive candidiasis were used to evaluate the relationship between drug exposure and mycologic response using logistic regression.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Sixty-four infants 3\u2013119 days of age were included, of which 29 (45%) infants had invasive candidiasis. A 2-compartment PK model fits the data well. Allometric scaling was applied to clearance and volume normalized to the mean population weight (kg). The mean (standard deviation) estimates for clearance and volume in the central compartment were 0.07 (0.05) L\/h\/1.8\u2009kg and 0.61 (0.53) L\/1.8\u2009kg, respectively. No relationship between average daily area under concentration\u2013time curve or average daily area under concentration\u2013time curve:minimum inhibitory concentration ratio and mycologic response was demonstrated (<jats:italic toggle=\"yes\">P<\/jats:italic> &gt; 0.05). Although not statistically significant, mycologic response was numerically higher when area under concentration\u2013time curves were at or above the PD target.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>While a significant exposure\u2013response relationship was not found, PK\u2013PD experiments support higher exposures of micafungin in infants with invasive candidiasis. More patients would clarify this relationship; however, low incidence deters the feasibility of these studies.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000001957","type":"journal-article","created":{"date-parts":[[2018,5,15]],"date-time":"2018-05-15T23:33:03Z","timestamp":1526427183000},"page":"580-585","source":"Crossref","is-referenced-by-count":8,"title":["Exposure\u2013Response Analysis of Micafungin in Neonatal Candidiasis"],"prefix":"10.1097","volume":"37","author":[{"given":"Laura L.","family":"Kovanda","sequence":"first","affiliation":[{"name":"Global Development, Antimicrobial Pharmacodynamics and Therapeutics, Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom"},{"name":"Clinical Pharmacology and Exploratory Development, Astellas Pharma Global Development, Inc., Northbrook, Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas J.","family":"Walsh","sequence":"additional","affiliation":[{"name":"Weill department of medicine, Weill Cornell Medicine of Cornell University, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel K.","family":"Benjamin","sequence":"additional","affiliation":[{"name":"Duke Department of Pediatrics, Duke University Medical Center, Durham, North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Arrieta","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease Children\u2019s Hospital of Orange County, Orange County, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Kaufman","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Virginia Health System, Charlottesville, Virginia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. Brian","family":"Smith","sequence":"additional","affiliation":[{"name":"Duke Department of Pediatrics, Duke University Medical Center, Durham, North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Manzoni","sequence":"additional","affiliation":[{"name":"Neonatology and NICU, Azienda Ospedaliera OIRM\u2013Sant\u2019Anna Hospital, Torino, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit V.","family":"Desai","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Exploratory Development, Astellas Pharma Global Development, Inc., Northbrook, Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsunori","family":"Kaibara","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Exploratory Development, Astellas Pharma Global Development, Inc., Northbrook, Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter L.","family":"Bonate","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Exploratory Development, Astellas Pharma Global Development, Inc., Northbrook, Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William W.","family":"Hope","sequence":"additional","affiliation":[{"name":"Global Development, Antimicrobial Pharmacodynamics and Therapeutics, Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230912","doi-asserted-by":"crossref","first-page":"F454","DOI":"10.1136\/archdischild-2012-303350","article-title":"Update on the management of Candida infections in preterm neonates.","volume":"100","author":"Manzoni","year":"2015","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"R2-20230912","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s12281-015-0238-x","article-title":"Neonatal candidiasis: new insights into an old problem at a unique host-pathogen interface.","volume":"9","author":"Arsenault","year":"2015","journal-title":"Curr Fungal Infect Rep"},{"key":"R3-20230912","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.idc.2005.05.007","article-title":"Neonatal candidiasis.","volume":"19","author":"Smith","year":"2005","journal-title":"Infect Dis Clin North Am"},{"key":"R4-20230912","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/sj.jp.7211068","article-title":"Mortality following blood culture in premature infants: increased with Gram-negative bacteremia and candidemia, but not Gram-positive bacteremia.","volume":"24","author":"Benjamin","year":"2004","journal-title":"J Perinatol"},{"key":"R5-20230912","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/INF.0b013e31824f8426","article-title":"Commentary: pediatric antifungal drug development: lessons learned and recommendations for the future.","volume":"31","author":"Watt","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"R6-20230912","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1001\/jama.292.19.2357","article-title":"Neurodevelopmental and growth impairment among extremely low-birth-weight infants with neonatal infection.","volume":"292","author":"Stoll","year":"2004","journal-title":"JAMA"},{"key":"R7-20230912","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1542\/peds.2004-2292","article-title":"Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months.","volume":"117","author":"Benjamin","year":"2006","journal-title":"Pediatrics"},{"key":"R8-20230912","article-title":"Clinical practice guideline for the management of Candidiasis: 2016 update by the Infectious Diseases Society of America.","author":"Pappas","journal-title":"Clin Infect Dis"},{"issue":"suppl 7","key":"R9-20230912","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/1469-0691.12041","article-title":"ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT).","volume":"18","author":"Ullmann","year":"2012","journal-title":"Clin Microbiol Infect"},{"issue":"suppl 7","key":"R10-20230912","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/1469-0691.12039","article-title":"ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients.","volume":"18","author":"Cornely","year":"2012","journal-title":"Clin Microbiol Infect"},{"issue":"suppl 7","key":"R11-20230912","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/1469-0691.12040","article-title":"ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp.","volume":"18(","author":"Hope","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"R12-20230912","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1517\/14740338.2011.557062","article-title":"Accumulated safety data of micafungin in therapy and prophylaxis in fungal diseases.","volume":"10","author":"Cornely","year":"2011","journal-title":"Expert Opin Drug Saf"},{"key":"R13-20230912","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.1097\/INF.0b013e3182127eaf","article-title":"Safety of micafungin in pediatric clinical trials.","volume":"30","author":"Arrieta","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"R15-20230912","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1086\/524063","article-title":"The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates.","volume":"197","author":"Hope","year":"2008","journal-title":"J Infect Dis"},{"key":"R16-20230912","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/clpt.2009.200","article-title":"Safety and pharmacokinetics of repeat-dose micafungin in young infants.","volume":"87","author":"Benjamin","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"R18-20230912","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1097\/01.inf.0000245103.07614.e1","article-title":"The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants.","volume":"25","author":"Heresi","year":"2006","journal-title":"Pediatr Infect Dis J"},{"key":"R19-20230912","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1097\/INF.0b013e31824ab9b0","article-title":"Pharmacokinetics of micafungin in pediatric patients with invasive candidiasis and candidemia.","volume":"31","author":"Undre","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"R20-20230912","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1097\/INF.0b013e31817275e6","article-title":"Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial.","volume":"27","author":"Queiroz-Telles","year":"2008","journal-title":"Pediatr Infect Dis J"},{"key":"R21-20230912","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/FTD.0b013e31825c4ba6","article-title":"Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R.","volume":"34","author":"Neely","year":"2012","journal-title":"Ther Drug Monit"},{"key":"R22-20230912","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1128\/AAC.01679-09","article-title":"Population pharmacokinetics of micafungin in neonates and young infants.","volume":"54","author":"Hope","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"R23-20230912","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1128\/AAC.03736-14","article-title":"Population pharmacokinetics of micafungin and its metabolites M1 and M5 in children and adolescents.","volume":"59","author":"Hope","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"R24-20230912","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0732-8893(93)90020-8","article-title":"Lysis-centrifugation blood cultures in the detection of tissue-proven invasive candidiasis. Disseminated versus single-organ infection.","volume":"17","author":"Berenguer","year":"1993","journal-title":"Diagn Microbiol Infect Dis"},{"key":"R25-20230912","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.clp.2014.10.008","article-title":"The epidemiology and diagnosis of invasive candidiasis among premature infants.","volume":"42","author":"Kelly","year":"2015","journal-title":"Clin Perinatol"},{"key":"R26-20230912","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/00006454-199807000-00004","article-title":"Incidence, presenting features, risk factors and significance of late onset septicemia in very low birth weight infants. The National Institute of Child Health and Human Development Neonatal Research Network.","volume":"17","author":"Fanaroff","year":"1998","journal-title":"Pediatr Infect Dis J"},{"key":"R27-20230912","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1093\/jpids\/piv014","article-title":"(1\u21923)-\u03b2-d-Glucan in cerebrospinal fluid as a biomarker for Candida and Aspergillus infections of the central nervous system in pediatric patients.","volume":"5","author":"Salvatore","year":"2016","journal-title":"J Pediatric Infect Dis Soc"},{"key":"R29-20230912","doi-asserted-by":"crossref","first-page":"e865","DOI":"10.1542\/peds.2009-3412","article-title":"Neonatal candidiasis: epidemiology, risk factors, and clinical judgment.","volume":"126","author":"Benjamin","year":"2010","journal-title":"Pediatrics"},{"key":"R30-20230912","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1542\/peds.2013-0671","article-title":"Changes in the incidence of candidiasis in neonatal intensive care units.","volume":"133","author":"Aliaga","year":"2014","journal-title":"Pediatrics"},{"key":"R31-20230912","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1093\/jac\/dkw298","article-title":"Pharmacodynamics for antifungal drug development: an approach for acceleration, risk minimization and demonstration of causality.","volume":"71","author":"Hope","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"R32-20230912","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/INF.0b013e3181910e2d","article-title":"Pharmacokinetics of an elevated dosage of micafungin in premature neonates.","volume":"28","author":"Smith","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"R33-20230912","doi-asserted-by":"crossref","first-page":"7333","DOI":"10.1128\/AAC.01172-16","article-title":"High-dose micafungin for preterm neonates and infants with invasive and central nervous system Candidiasis.","volume":"60","author":"Auriti","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"R34-20230912","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s40262-016-0436-x","article-title":"Allometric scaling of clearance in paediatric patients: when does the magic of 0.75 fade?","volume":"56","author":"Calvier","year":"2017","journal-title":"Clin Pharmacokinet"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006454-201806000-00020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T22:48:03Z","timestamp":1694558883000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201806000-00020"}},"subtitle":["Pooled Analysis of Two Clinical Trials"],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000001957","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]}}}